On July 22, 2025, B of A Securities released an updated analyst report on CRISPR Therapeutics (CRSP, Financial). The report, issued by analyst Geoff Meacham, highlights a change in the price target for the biotechnology company.
The current price target for CRISPR Therapeutics (CRSP, Financial) has been adjusted to $78.00 USD, down from the previous target of $79.00 USD. This represents a decrease of approximately 1.27% in the price target. Despite this adjustment, B of A Securities has maintained its "Buy" rating on the stock.
The decision to adjust the price target comes amidst a series of evaluations by analysts seeking to provide accurate guidance for investors. The consistency in the "Buy" rating suggests continued confidence in CRISPR Therapeutics' (CRSP, Financial) potential for growth in the biotechnology sector.
Investors will be closely monitoring CRISPR Therapeutics (CRSP, Financial) as it continues to navigate the dynamic landscape of genetic therapies and treatments, aiming to leverage its innovative approach in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.80 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 22.21% from the current price of $66.11. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $36.68, suggesting a downside of 44.52% from the current price of $66.11. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
